Evidence Grade B — Strong clinical evidence. 563 published studies, 504 human. 274 registered clinical trials.
Medically reviewed by a licensed medical professional
Nesiritide (previously sold as Natrecor) is a recombinant form of BNP — a hormone naturally released by the heart when it is under stress from fluid overload. It was previously approved for acute heart failure but was withdrawn from the US market in 2020. Its story is a cautionary tale about how early enthusiasm can be reversed by rigorous outcomes data.
Nesiritide is also known by these brand and alternate names:
563 published studies: 504 human, 9 animal, 2 in-vitro, 199 reviews
Nesiritide was marketed as Natrecor (approved August 2001) for acute decompensated heart failure. The NDA was withdrawn in June 2020. It was widely adopted after initial approval but came under significant scrutiny following a 2005 analysis that raised concerns about potential increases in mortality and kidney damage.
The large ASCEND-HF trial (over 7,000 patients) subsequently showed that nesiritide provided only modest symptom relief over standard diuretics, with no mortality benefit and a signal toward increased low blood pressure episodes. These results, combined with the earlier safety concerns and the availability of effective alternatives, led to its commercial withdrawal. Nesiritide illustrates how early enthusiasm for a biologically logical therapy can be tempered by rigorous outcomes data.
BNP is the heart's natural distress signal when it is overloaded with fluid. Nesiritide mimics this signal by activating natriuretic peptide receptors, which causes blood vessels to dilate (reducing the workload on the heart), promotes sodium and water excretion by the kidneys (reducing fluid overload), and suppresses the hormonal systems that drive fluid retention. These combined effects rapidly reduce the pressure and volume burden on a failing heart.
Nesiritide was widely adopted after its initial approval and reached over $700 million in peak sales. However, a 2005 analysis raised concerns about potential increases in mortality and kidney damage. The definitive ASCEND-HF trial (over 7,000 patients) subsequently showed that nesiritide provided only marginal symptom relief over standard diuretics, with no mortality benefit — making its high cost unjustifiable. The drug's trajectory from rapid uptake to meta-analysis concerns to a landmark negative trial to market withdrawal is a textbook case study in evidence-based medicine. Interestingly, the natriuretic peptide pathway was later validated through sacubitril/valsartan (Entresto), which raises endogenous natriuretic peptides through enzyme inhibition rather than injecting them directly.
PeptideTrace tracks 274 registered clinical trials for Nesiritide sourced from ClinicalTrials.gov.
An Efficacy and Safety Study for Nesiritide in Heart Failure Patients With Reduced Kidney Function Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (CPB Pump or Heart Lung Machine)
Natriuretic Peptides and Metabolic Risk in Obesity
Boston Medical Center Ultrasound Decongestion Study in Heart Failure
Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock
Prospective Evaluation of AI-ECG for SHD Detection
Health Canada Market Authorisation
Nesiritide is a 32-amino-acid recombinant peptide identical to endogenous human B-type natriuretic peptide (BNP). It was formerly marketed as Natrecor for acute decompensated heart failure. The NDA was withdrawn in June 2020.
Nesiritide binds natriuretic peptide receptor-A (NPR-A), a transmembrane guanylyl cyclase, increasing intracellular cGMP in vascular smooth muscle and renal tubular cells. This produces arterial and venous vasodilation (reducing preload and afterload), natriuresis and diuresis, and suppression of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS). These hemodynamic effects mirror the physiological role of endogenous BNP in heart failure compensation.
Nesiritide was marketed as Natrecor (Scios/Johnson & Johnson, FDA approved August 2001) for acute decompensated heart failure (dyspnea relief). The drug was widely adopted after approval but came under scrutiny after a 2005 meta-analysis by Sackner-Bernstein raised concerns about increased mortality and renal toxicity. The ASCEND-HF trial (N=7,141; NEJM 2011) was designed to address these concerns: 30-day death or rehospitalization was 9.4% versus 10.1% for placebo (P=0.31—no benefit). Dyspnea improvement did not meet prespecified significance thresholds. No renal toxicity was observed. Manufacturing was discontinued February 2018; NDA withdrawn June 15, 2020 (85 FR 28950).
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Linaclotide is marketed as Linzess (approved August 2012). It is taken as a daily oral capsule on an empty stomach, at least 30 minutes before the first meal. The recommended dose is 290 mcg for IBS-C and 72 or 145 mcg for chronic constipation. In clinical trials, approximately 34% of IBS-C patients met the composite improvement endpoint compared to 17% on placebo. Diarrhoea is the most common side effect (approximately 20%) and the leading reason for discontinuation. Linaclotide has a boxed warning against use in children under 6 years due to deaths in young mice, though no such events have been reported in humans. It competes with plecanatide (which targets the same pathway) and other IBS-C treatments.
Elamipretide (Forzinity) was approved by the FDA for Barth syndrome based on the TAZPOWER trial. The randomised crossover phase (12 patients) did not meet its primary endpoints, but the open-label extension (168 weeks) demonstrated durable improvements in walking distance and muscle strength that formed the basis for approval. Barth syndrome affects approximately 1 in 300,000–400,000 births. A larger Phase III trial in primary mitochondrial myopathy (218 patients, MMPOWER-3) did not meet its primary endpoint, and the drug was not approved for that broader indication. Elamipretide remains approved exclusively for Barth syndrome. See also SS-31 (#158) for the research compound context.
Glucagon has been available as an emergency injection since the 1960s and remains the standard rescue treatment for severe hypoglycaemia. Recent innovation has focused on making it easier to administer in emergencies. Baqsimi, approved in 2019, was the first needle-free option as a nasal powder. Gvoke, also approved in 2019, eliminated the need to mix and reconstitute the medication before injection — a significant advance since severe hypoglycaemia often impairs the ability to follow complex preparation steps. Dasiglucagon (Zegalogue), a next-generation stable liquid glucagon approved in 2021, further improved on the convenience of rescue administration. Beyond emergency rescue, glucagon's receptor is now a major research target — dual and triple agonists combining glucagon receptor activity with GLP-1 (such as survodutide and retatrutide) are in advanced clinical trials for obesity and metabolic disease.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
